8 September 2016
Biopharmaceutical company AstraZeneca and the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) have announced a $10 million, five-year global public-private partnership that will expand access to HIV/AIDS and hypertension services by offering them in an integrated way at existing HIV/AIDS sites supported by PEPFAR, starting in Kenya.
For AstraZeneca, the sizable patient reach of PEPFAR represents an opportunity to screen for hypertension during clinical triage. For PEPFAR, the ability to make hypertension screening available to men alongside HIV/AIDS services supports efforts to identify harder-to-reach patients for HIV testing, particularly males aged 25-50, and provide proper referral to HIV/AIDS treatment. Using joint implementation, both programs are expected to increase their impact.
“AstraZeneca shares PEPFAR’s vision of improving the health and lives of underserved communities in sub-Saharan Africa. Increasing rates of hypertension and cardiovascular disease in the region threaten individuals, families and communities, and burden already-stressed health systems. We are honored and proud to join with PEPFAR to improve access to vital testing and treatment which help stem the tide of both hypertension and HIV/AIDS,” said Mark Mallon, EVP International, member of the Senior Executive Team and Healthy Heart Africa (HHA) sponsor at AstraZeneca.
Ambassador Deborah L. Birx, M.D., U.S. Global AIDS Coordinator and Special Representative for Global Health Diplomacy, said: “Together, we have made remarkable progress in the global response to HIV/AIDS. Yet, we need innovative approaches to better identify and serve harder to reach populations, including men, who too often only present for care when they are very ill. Through this new partnership with AstraZeneca we will enhance our ability to deliver earlier and more effective HIV/AIDS testing and treatment for working-age men in two high-prevalence counties in Kenya.”